Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 335mg equivalent to 300 mg ranitidine - film coated tablet - 300 mg - active: ranitidine hydrochloride 335mg equivalent to 300 mg ranitidine excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc   purified water titanium dioxide - indicated for the treatment of duodenal ulcer, and benign gastric ulcer, including that associated with non-steroidal anti- inflammatory agents.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

viatris limited - ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg - film coated tablet - 150 mg - active: ranitidine hydrochloride 167.5mg equivalent to ranitidine 150 mg excipient: castor oil colloidal silicon dioxide croscarmellose sodium hypromellose e-15 iron oxide yellow isopropyl alcohol magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - symptomatic relief of heartburn, dyspepsia and hyperacidity in adults and children over 12 years.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

wockhardt usa llc - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for 1 year. - treatment of gerd. symptoma

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

wockhardt limited - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 15 mg in 1 ml - - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for 1 year. - treatment of gerd. symptoma

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - ranitidine hydrochloride - oral tablet - 300mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

contract pharmacy services-pa - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine hydrochloride 150 mg - ranitidine tablets are indicated in: 1. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of rantidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acuter ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). 4. short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

state of florida doh central pharmacy - ranitidine (unii: 884kt10yb7) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine tablets are indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

nucare plc - ranitidine hydrochloride - oral tablet - 75mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

vantage - ranitidine hydrochloride - oral tablet - 75mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - ranitidine hydrochloride - oral tablet - 75mg